[HIGHLIGHTS] U.S. Approves First Bronchiolitis Vaccine

U.S. approves first vaccine against respiratory syncytial virus (RSV), responsible for bronchiolitis and tens of thousands of deaths each year.

Vaccine developed by British pharmaceutical giant GSK for adults 60 years of age and older. Last week, the same vaccine received a positive opinion from the European Medicines Agency. Pfizer and Moderna are also each developing an RSV vaccine for the elderly and expect a decision from the U.S., FDA in May.